LeadIQ logo
Learn more at LeadIQ.com
✕

Access Insights for Volastra Therapeutics and Millions of Other Companies

Sign up for full access to Volastra Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Insights

Loading spinner
Gathering insights about Volastra Therapeutics…

Similar companies to Volastra Therapeutics

✕

Access Insights for Volastra Therapeutics and Millions of Other Companies

Sign up for full access to Volastra Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Volastra Therapeutics Tech Stack

Volastra Therapeutics uses 8 technology products and services including WordPress, MySQL, git, and more. Explore Volastra Therapeutics's tech stack below.

  • WordPress
    Content Management System
  • MySQL
    Database
  • git
    Development
  • Microsoft Excel
    Editors
  • Google Font API
    Font Scripts
  • Google Cloud
    Infrastructure As A Service
  • RSS
    Miscellaneous
  • HSTS
    Security

Media & News

Volastra Therapeutics's Email Address Formats

Volastra Therapeutics uses at least 1 format(s):
Volastra Therapeutics Email FormatsExamplePercentage
FLast@volastratx.comJDoe@volastratx.com
49%
First@volastratx.comJohn@volastratx.com
1%
FLast@volastratx.comJDoe@volastratx.com
49%
First@volastratx.comJohn@volastratx.com
1%

Frequently Asked Questions

Where is Volastra Therapeutics's headquarters located?

Minus sign iconPlus sign iconVolastra Therapeutics's main headquarters is located at 1361 Amsterdam Ave 520 New York, New York 10027 US. The company has employees across 3 continents, including North AmericaAfricaEurope.

What is Volastra Therapeutics's official website and social media links?

Minus sign iconPlus sign iconVolastra Therapeutics's official website is volastratx.com and has social profiles on LinkedIn.

How much revenue does Volastra Therapeutics generate?

Minus sign iconPlus sign icon As of September 2024, Volastra Therapeutics's annual revenue reached $3.8M.

What is Volastra Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign iconVolastra Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Volastra Therapeutics have currently?

Minus sign iconPlus sign iconAs of September 2024, Volastra Therapeutics has approximately 44 employees across 3 continents, including North AmericaAfricaEurope. Key team members include Chief Scientific Officer: M. S.Head Of R&d And Chief Medical Officer: S. D.Ceo: C. H.. Explore Volastra Therapeutics's employee directory with LeadIQ.

What industry does Volastra Therapeutics belong to?

Minus sign iconPlus sign iconVolastra Therapeutics operates in the Biotechnology Research industry.

What technology does Volastra Therapeutics use?

Minus sign iconPlus sign iconVolastra Therapeutics's tech stack includes WordPressMySQLgitMicrosoft ExcelGoogle Font APIGoogle CloudRSSHSTS.

What is Volastra Therapeutics's email format?

Minus sign iconPlus sign iconVolastra Therapeutics's email format typically follows the pattern of . Find more Volastra Therapeutics email formats with LeadIQ.

How much funding has Volastra Therapeutics raised to date?

Minus sign iconPlus sign icon As of September 2024, Volastra Therapeutics has raised $15M in funding. The last funding round occurred on May 30, 2024 for $15M.

When was Volastra Therapeutics founded?

Minus sign iconPlus sign iconVolastra Therapeutics was founded in 2019.
Volastra Therapeutics

Volastra Therapeutics

Biotechnology ResearchNew York, United States11-50 Employees

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline.  Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1  clinical trials for cancers with high levels of chromosomal instability.

✕

Access Insights for Volastra Therapeutics and Millions of Other Companies

Sign up for full access to Volastra Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Section iconCompany Overview

Headquarters
1361 Amsterdam Ave 520 New York, New York 10027 US
Website
volastratx.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $15M

    Volastra Therapeutics has raised a total of $15M of funding over 4 rounds. Their latest funding round was raised on May 30, 2024 in the amount of $15M.

  • $10M

    Volastra Therapeutics's revenue is in the range of $10M

Section iconFunding & Financials

  • $15M

    Volastra Therapeutics has raised a total of $15M of funding over 4 rounds. Their latest funding round was raised on May 30, 2024 in the amount of $15M.

  • $10M

    Volastra Therapeutics's revenue is in the range of $10M

Company Leadership

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

✕

Access Insights for Volastra Therapeutics and Millions of Other Companies

Sign up for full access to Volastra Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.